Eversept Partners, LP Immunovant, Inc. Transaction History

Eversept Partners, LP

  • $1.26 Billion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$25.1 - $31.61 $4.08 Million - $5.14 Million
-162,617 Reduced 63.64%
92,909 $2.45 Million
Q1 2024

May 15, 2024
BUY
$30.27 - $43.79 $4.29 Million - $6.21 Million
141,733 Added 124.55%
255,526 $8.26 Million
Q4 2023

Feb 14, 2024
BUY
$31.31 - $44.19 $3.56 Million - $5.03 Million
113,793 New
113,793 $4.79 Million
Q3 2021

Nov 15, 2021
SELL
$7.01 - $11.37 $772,382 - $1.25 Million
-110,183 Closed
0 $0
Q2 2021

Nov 08, 2023
SELL
$9.4 - $16.85 $1.13 Million - $2.02 Million
-120,000 Reduced 52.13%
110,183 $1.16 Million
Q2 2021

Aug 16, 2021
SELL
$9.4 - $16.85 $1.13 Million - $2.02 Million
-120,000 Reduced 52.13%
110,183 $1.17 Million
Q1 2021

Nov 08, 2023
BUY
$13.08 - $49.6 $3.01 Million - $11.4 Million
230,183 New
230,183 $3.69 Million
Q1 2021

May 13, 2021
BUY
$13.08 - $49.6 $2.85 Million - $10.8 Million
217,917 Added 1776.59%
230,183 $3.69 Million
Q2 2020

Nov 08, 2023
SELL
$13.87 - $28.44 $896,002 - $1.84 Million
-64,600 Reduced 84.04%
12,266 $298,000
Q2 2020

Aug 13, 2020
SELL
$13.87 - $28.44 $896,002 - $1.84 Million
-64,600 Reduced 84.04%
12,266 $299,000
Q4 2019

Nov 08, 2023
BUY
$10.02 - $16.4 $770,197 - $1.26 Million
76,866 New
76,866 $1.22 Million
Q4 2019

Feb 13, 2020
BUY
$10.02 - $16.4 $770,197 - $1.26 Million
76,866 New
76,866 $1.22 Million

Others Institutions Holding IMVT

# of Institutions
212
Shares Held
66.9M
Call Options Held
2.3M
Put Options Held
631K
View Full List

About Immunovant, Inc.

IMVT Quotes by TradingView
  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email